Literature DB >> 7792127

Otitis media complications and treatment failures: implications of pneumococcal resistance.

M D Poole1.   

Abstract

Classic complications of untreated otitis media include meningitis, lateral sinus thrombosis and chronic suppurative otitis media. In the past, in countries where otitis media is usually treated, complications have been rare, because of the good activity of almost all orally administered antibiotics against the most common cause of complications, Streptococcus pneumoniae. Treatment failures were usually caused by beta-lactamase-producing nontypable Haemophilus influenzae or by Moraxella (Branhamella) catarrhalis and were rarely associated with serious systemic infections. With the advent of multidrug-resistant pneumococci, however, serious and fatal infections can occur in the face of our most potent antimicrobial agents. The consequences of the emergence of multidrug-resistant pneumococci are likely to include more persistent purulent otitis media, increased usage of broad-spectrum antibiotics, an increase in surgical treatment rates for otitis media and, eventually, an increase in suppurative complications of otitis media. Medical treatment failures probably already surpass eustachian tube dysfunction as the most common reason for tympanostomy tube insertion. Multidrug-resistant pneumococci may be expected to change the way in which primary and secondary care is currently administered.

Entities:  

Mesh:

Year:  1995        PMID: 7792127     DOI: 10.1097/00006454-199504001-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

Review 1.  Rational prescribing of antibacterials in ambulatory children.

Authors:  J E Hoppe
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

2.  A new rat model of otitis media caused by Streptococcus pneumoniae: conditions and application in immunization protocols.

Authors:  L T van der Ven; G P van den Dobbelsteen; B Nagarajah; H van Dijken; P M Dortant; J G Vos; P J Roholl
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

3.  Comparative efficacy and safety evaluation of cefaclor VS amoxycillin + calvulanate in children with Acute Otitis Media (AOM).

Authors:  Mukesh Aggarwal; Ramanuj Sinha; M Vasudeva Murali; Prita Trihan; P K Singhal
Journal:  Indian J Pediatr       Date:  2005-03       Impact factor: 1.967

4.  A Five-year Review on the Etiology and Antimicrobial Susceptibility Pattern of Otitis Media Pathogens in Jordanian Children.

Authors:  Mohammad Al-Shara
Journal:  Oman Med J       Date:  2012-09

5.  Temporal and spatial distribution of clonal complexes of Streptococcus pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004.

Authors:  Heather Amrine-Madsen; Johan Van Eldere; Robertino M Mera; Linda A Miller; James A Poupard; Elizabeth S Thomas; Wendy S Halsey; Julie A Becker; F Patrick O'Hara
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

6.  Risk factors for development of multiple-class resistance to Streptococcus pneumoniae Strains in Belgium over a 10-year period: antimicrobial consumption, population density, and geographic location.

Authors:  Johan Van Eldere; Robertino M Mera; Linda A Miller; James A Poupard; Heather Amrine-Madsen
Journal:  Antimicrob Agents Chemother       Date:  2007-08-06       Impact factor: 5.191

7.  Pharmacokinetics and efficacy of linezolid in a gerbil model of Streptococcus pneumoniae-induced acute otitis media.

Authors:  William R Humphrey; Mark H Shattuck; Raymond J Zielinski; Ming-Shang T Kuo; John J Biermacher; Donald P Smith; Jana L Jensen; Ronda D Schaadt; Gary E Zurenko; Ivan M Richards
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

8.  Gradenigo's Syndrome with Carotid Septic Stenosis.

Authors:  Ana Sousa Menezes; Daniela Ribeiro; Filipa Balona; Ricardo Maré; Cátia Azevedo; Jaime Rocha; Luís Dias
Journal:  Case Rep Otolaryngol       Date:  2020-02-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.